- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05981846
Um estudo de Fase II para avaliar a segurança e a imunogenicidade do BIMERVAX® quando coadministrado com a vacina contra influenza sazonal (SIIV) em adultos com mais de 65 anos de idade totalmente vacinados contra COVID-19
Um estudo multicêntrico, randomizado, duplo-cego e de fase II para avaliar a segurança e a imunogenicidade de BIMERVAX® quando coadministrado com antígeno de superfície sazonal, vacina contra influenza adjuvante inativada (SIIV) em adultos com mais de 65 anos de idade totalmente vacinados contra COVID -19
This is a Phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen inactivated adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This is a Phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen inactivated adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19.
In this study approximately 300 adults aged 65 or older will be enrolled and followed for 1 month after study treatment. Safety and immunogenicity of all participants will be assessed.
The participants will be randomised 1:1:1 to one of the following three cohorts:
- Cohort 1: approximately 100 participants will receive one dose of SIIV in one arm + one dose of placebo in the other arm, at Day 0.
- Cohort 2: approximately 100 participants will receive one dose of BIMERVAX® in one arm + 1 dose of placebo in the other arm, at Day 0.
- Cohort 3: approximately 100 participants will receive one dose SIIV in one arm + one dose of BIMERVAX® in the other arm, at Day 0.
All participants will receive two administrations at Day 0 and will be followed for 1 month. All subjects will be closely observed for 15 minutes after vaccination on site. The study will be double-blind, both the participant and the physician (care provider) will be blinded. Participants will be provided with a participant paper diary on Day 0 to record solicited local and systemic reactions after vaccination through Day 7. Unsolicited local and systemic adverse events, SAEs and AESIs, will be recorded through Day 28 (end of study).
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
A Coruña
-
A Coruña, A Coruña, Espanha, 15011
- Hospital HM Modelo
-
Santiago de Compostela, A Coruña, Espanha, 15706
- Hospital Clínico Universitario de Santiago
-
-
Barcelona
-
Badalona, Barcelona, Espanha, 08916
- Hospital Germans Trias i Pujol
-
Barcelona, Barcelona, Espanha, 08036
- Hospital Clínic de Barcelona
-
Centelles, Barcelona, Espanha, 08540
- CAP Centelles
-
-
Girona
-
Girona, Girona, Espanha, 17001
- Hospital Josep Trueta
-
-
Málaga
-
Málaga, Málaga, Espanha, 29010
- Hospital Regional de Málaga
-
-
Valladolid
-
Valladolid, Valladolid, Espanha, 47003
- Hospital Clínico de Valladolid
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Adults aged 65 or older at Day 0.
-
Are willing and able to sign the informed consent and can comply with all study visits and procedures.
-
Participant must have received at least a primary scheme of an mRNA vaccine (2 doses). Booster doses or previous COVID-19 infections are allowed. Last dose must have been administered at least 6 months before Day 0. History of COVID-19 infection is allowed if occurred at least >30 days before Day 0.
-
Have a negative Rapid Antigen Test (RAT) at Day 0 before vaccinations.
-
Adults determined by clinical assessment, including medical history and clinical judgement, to be eligible for the study, including adults with pre-existing chronic and stable diseases (non-immunocompromised), if these are stable and well-controlled according to the investigator's judgment.
Exclusion Criteria:
-
Acute illness with fever ≥ 38.0°C at Day 0 or within 24 hours prior to vaccination. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator.
-
Allergy to egg proteins (egg or egg products) or chicken proteins.
-
History of Guillain-Barré syndrome (GBS)
-
History of COVID-19 infection (described as a positive RAT or PCR), in the previous 30 days before Day 0.
-
Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behaviour that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
-
History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g. anaphylaxis) to any component of the study intervention(s).
-
Immunocompromised individuals defined as those with primary and secondary immune deficiencies and those receiving chemotherapy or immunosuppressant drugs other than steroids and glucocorticoids (maximum 30mg/day of prednisone, or equivalent, by any administration route for a maximum of 30 consecutive days), within 90 days prior to vaccination or during the study.
-
Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
-
Receipt of blood-derived immune globulins, blood, or blood-derived products in the past 3 months.
-
Participation in other studies involving study intervention within 28 days prior to screening and/or during study participation.
-
Received any non-study vaccine within 14 days before or after screening. For live or attenuated vaccines, 4 weeks before or after screening.
-
History of a diagnosis or other conditions that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: BIMERVAX + SIIV
|
One dose of booster vaccine One dose |
|
Comparador Ativo: BIMERVAX + PLACEBO
|
One dose of booster vaccine |
|
Comparador Ativo: SIIV + PLACEBO
|
One dose |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number, percentage, and characteristics of solicited local and systemic reactions through Day 7 after vaccination.
Prazo: Day 0, Day 7
|
To assess and compare the safety and tolerability of BIMERVAX® coadministered with SIIV in adults with respect to each vaccine administered alone. |
Day 0, Day 7
|
|
Number, percentage, and characteristics of unsolicited local and systemic adverse events (AEs) through the end of the study.
Prazo: Day 0, Day 7, Day 28
|
To assess and compare the safety and tolerability of BIMERVAX® coadministered with SIIV in adults with respect to each vaccine administered alone. |
Day 0, Day 7, Day 28
|
|
Number and percentage of serious adverse events (SAEs) through the end of the study.
Prazo: Day 0, Day 7, Day 28
|
To assess and compare the safety and tolerability of BIMERVAX® coadministered with SIIV in adults with respect to each vaccine administered alone. |
Day 0, Day 7, Day 28
|
|
Number and percentage of adverse events of special interest (AESI) through the end of the study
Prazo: Day 0, Day 7, Day 28
|
To assess and compare the safety and tolerability of BIMERVAX® coadministered with SIIV in adults with respect to each vaccine administered alone. |
Day 0, Day 7, Day 28
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Total binding antibody titers against SARS-CoV-2 RBD at Days 0 and 28
Prazo: Day 0, Day28
|
To determine and compare the immunogenicity measured by means of total antibodies against the Receptor Binding Domain of the Spike protein of SARS-CoV-2, measured by an electrochemiluminescence immunoassay (ECLIA) at Baseline and Day 28, in participants vaccinated with BIMERVAX® alone or coadministered with SIIV. |
Day 0, Day28
|
|
Geometric mean fold rise in total binding antibody titers against SARS-CoV-2 RBD at Day 28
Prazo: Day 0, Day28
|
To determine and compare the geometric mean fold rise (GMFR) in total binding antibody titers against the Receptor Binding Domain of the Spike protein of SARS-CoV-2 from Baseline to Day 28, in participants vaccinated with BIMERVAX® alone or coadministered with SIIV. |
Day 0, Day28
|
|
Influenza strain-specific HAI antibody titers at Days 0 and 28
Prazo: Day 0, Day28
|
To determine and compare the immunogenicity measured by influenza strain-specific antibody titers using a haemagglutination inhibition (HAI) assay at Baseline and Day 28, in participants vaccinated with SIIV alone or coadministered with BIMERVAX® |
Day 0, Day28
|
|
Geometric mean fold rise in influenza strain-specific HAI antibody titers at Day 28
Prazo: Day 0, Day28
|
To determine and compare the geometric mean fold rise (GMFR) in influenza strain-specific antibody titers measured by haemagglutination inhibition (HAI) assay from Baseline to Day 28, in participants vaccinated with SIIV alone or coadministered with BIMERVAX®. |
Day 0, Day28
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Teresa Prat, Hipra Scientific, S.L.U
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- HIPRA-HH-11
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .